← Back to Search

Diagnostic Test

Parkinson's disease for Autonomic Failure

N/A
Waitlist Available
Led By Todd Levine, MD
Research Sponsored by CND Life Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Summary

The Synuclein-One Study will be evaluating α-synuclein in patients with Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies and Pure Autonomic Failure. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.

Eligible Conditions
  • Autonomic Failure
  • Parkinson's Disease
  • Multiple System Atrophy
  • Dementia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
1
2
3

Trial Design

5Treatment groups
Experimental Treatment
Group I: Pure Autonomic FailureExperimental Treatment1 Intervention
Looking for 60 patients with a clinically established diagnosis of Pure Autonomic Failure between 40-99 years of age.
Group II: Parkinson's diseaseExperimental Treatment1 Intervention
Looking for 105 patients with a clinically established diagnosis of Parkinson's disease between 40-99 years of age.
Group III: Multiple System AtrophyExperimental Treatment1 Intervention
Looking for 40 patients with a clinically established diagnosis of Multiple System Atrophy between 40-99 years of age.
Group IV: Healthy ControlsExperimental Treatment1 Intervention
No history of clinical or symptoms suggestive of Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies or Pure Autonomic Failure between 40-99 years of age.
Group V: Dementia with Lewy bodiesExperimental Treatment1 Intervention
Looking for 95 patients with a clinically established diagnosis of Dementia with Lewy bodies between 40-99 years of age.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Skin Biopsy
2015
Completed Phase 4
~680

Find a Location

Who is running the clinical trial?

CND Life SciencesLead Sponsor
2 Previous Clinical Trials
160 Total Patients Enrolled
Todd Levine, MDPrincipal InvestigatorCND Life Sciences: www.cndlifesciences.com
2 Previous Clinical Trials
110 Total Patients Enrolled
~92 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top